The human ATP-binding cassette (ABC) transporter ABCB6 has been described as a mitochondrial porphyrin transporter essential for heme biosynthesis 1 , but it is also suspected to contribute to anticancer drug resistance [2] [3] [4] , as do other ABC transporters located at the plasma membrane. We identified ABCB6 as the genetic basis of the Lan blood group antigen expressed on red blood cells but also at the plasma membrane of hepatocellular carcinoma (HCC) cells, and we established that ABCB6 encodes a new blood group system (Langereis, Lan). Targeted sequencing of ABCB6 in 12 unrelated individuals of the Lan(−) blood type identified 10 different ABCB6 null mutations. This is the first report of deficient alleles of this human ABC transporter gene. Of note, Lan(−) (ABCB6 −/− ) individuals do not suffer any clinical consequences, although their deficiency in ABCB6 may place them at risk when determining drug dosage.
Blood group antigens arise from genetic polymorphisms and define numerous differences between individuals, which can have tragic consequences in blood transfusions or pregnancy. Although the genetic loci of most blood group antigens have been identified 5, 6 , with direct implications for transfusion medicine and obstetrics, the genetic basis for some blood group antigens remains unknown, despite their clinical significance. This is the case for the Lan blood group antigen, which can cause severe hemolytic transfusion reactions 7 as well as hemolytic disease of the fetus and newborn (HDFN) 8, 9 . Lan is a high-frequency antigen that is not linked to any known blood group system, strongly suggesting that it is encoded by an uncharacterized genetic locus. The Lan(−) blood type is very rare worldwide and seems to be inherited as a recessive trait [7] [8] [9] [10] . Lan(−) individuals are usually identified during serological testing performed to investigate fetal-maternal incompatibility and/or to find compatible blood units for a patient who has developed an anti-Lan-that is, an alloantibody reacting with all red blood cells (RBCs) except those that are Lan(−). Transfusion support of individuals with an anti-Lan antibody is highly challenging, partly because of the scarcity of compatible blood donors but mainly because of the lack of reliable reagents for blood screening.
We have succeeded in generating the first monoclonal antibody with Lan specificity (OSK43; IgG 1 κ) from immortalized lymphocytes of a healthy Japanese Lan(−) woman who had developed anti-Lan antibody during pregnancy. OSK43 works in hemagglutination assays as well as flow cytometry and immunofluorescence analyses (Fig. 1a,b ), reacting with all tested RBCs except those that are Lan(−). We conducted a high-throughput screen by hemagglutination assay in Japan and identified 14 Lan(−) persons in 713,384 blood donors, establishing a frequency of 0.002% for the Lan(−) blood type in this population. The variation within and between individuals in Lan expression on RBCs seemed to be noticeably low when evaluated by flow cytometry with OSK43 (Fig. 1a,c) . Nevertheless, we observed that OSK43 showed a higher reactivity with umbilical cord blood than adult RBCs (Fig. 1d) , indicating that Lan expression can vary during development.
The specificity and affinity of OSK43 suggested that it could be an important reagent to elucidate the genetic basis of the Lan blood group antigen. In pursuit of this goal, we used OSK43 to purify the carrier molecule of the Lan antigen from RBCs. OSK43 immunoprecipitated a RBC membrane protein of approximately 80 kDa (Fig. 2a) , which was unambiguously identified as ABCB6 by mass spectrometry (Fig. 2b) . ABCB6 belongs to the large family of ABC transporters that use ATP to transport a wide variety of endogenous or xenobiotic substrates across cellular membranes 11 . On the basis of phylogenetic analysis, ABCB6 has been classified in the B subfamily along with the multidrug resistance P-glycoprotein (P-gp, also known as ABCB1). ABCB6 has been described as a porphyrin transporter located in the outer mitochondrial membrane that is highly expressed during erythroid differentiation and required for mitochondrial porphyrin uptake 1 . Nevertheless, ABCB6 has also been detected at the plasma membrane 12 , consistent with its suspected role in multidrug resistance. Indeed, increased expression of ABCB6 correlated with increased resistance of different cancer cell lines to drugs 2, 3 , and ABCB6 copy number was increased in the camptothecin-resistant cell line A549/CPT 4 . Thus, ABCB6 could transport anticancer drugs as well as endogenous substrates, similar to ABCB1 and other multidrug ABC transporters 13, 14 .
In order to validate ABCB6 as the genetic locus encoding the Lan blood group antigen, we first confirmed by protein blot analysis that ABCB6 was present in the membrane of Lan(+) RBCs (Fig. 2c, top,  lanes 3 and 6) . In contrast, we detected no ABCB6 gene products in Lan(−) RBCs (Fig. 2c , top, all other lanes), suggesting that null allele(s) of ABCB6 may be responsible for the Lan(−) blood type. We then established ABCB6-expressing clones of the human cell line K-562 and analyzed them by flow cytometry with OSK43. We observed that exogenous expression of ABCB6 in K-562 cells correlated with cell surface expression of the Lan antigen (Fig. 2d) . Taken together, these results confirm that the Lan blood group antigen is encoded by ABCB6 (at chromosome 2q36), thereby constituting a new blood group system. Of note, 30 blood group systems are currently recognized by the International Society for Blood Transfusion (ISBT), and none of these is encoded by an ABC transporter gene (see URLs).
To identify the ABCB6 mutations responsible for the Lan(−) blood type, we used the Lan(−) blood samples cryopreserved in the rare blood collection of the CNRGS (oldest sample dating to 1976). Of note, none of these Lan(−) blood samples was reactive with OSK43 by flow cytometry analysis ( Supplementary Fig. 1 ), confirming their original characterization as Lan(−). We extracted genomic DNA from these blood samples and sequenced ABCB6 (see Supplementary  Fig. 2 for sequencing strategy). From a cohort of 11 unrelated Lan(−) subjects, we identified 6 frameshift, 2 nonsense and 1 donor c L a n ( -) L a n ( -) L a n ( + ) L a n ( -) L a n ( -) L a n ( + ) L a n ( -) L a n ( -) (Fig. 2e and Table 1 , subjects 1-9, and Supplementary Fig. 3a-i) . Nine of these Lan(−) subjects were homozygous for a single mutation, and two were heterozygous for two mutations (Supplementary Table 1) . Analysis of the available pedigrees confirmed that the Lan(−) blood type results from recessive inheritance of these ABCB6 mutations (Supplementary Fig. 4) . We also sequenced the genomic DNA of the Japanese Lan(−) woman whose lymphocytes were used to generate OSK43 and found a new homozygous frameshift mutation in ABCB6 ( Table 1 , subject 10, and Supplementary Fig. 3j) , suggesting that wide variety of ABCB6 null alleles may exist. All ten ABCB6 null mutations identified in this study were absent in control (Lan(+)) subjects and in the NCBI dbSNP database (build 132).
Of note, although ABCB6 was expected to have an essential role in heme biosynthesis during erythroid differentiation by importing porphyrin into mitochondria 1 , Lan(−) (ABCB6 −/− ) individuals did not show anemia or abnormal erythropoiesis (Supplementary Fig. 5 ). This unexpected finding indicates either that no transporter is actually required for porphyrin import into the mitochondrial intermembrane space or, more likely, that another porphyrin transporter, as yet unknown, can compensate for the absence of ABCB6 at the mitochondrial outer membrane. We show here that ABCB6 is present at the plasma membrane of RBCs, which are devoid of mitochondria in mammals, suggesting that ABCB6 could have a role in exporting excess porphyrin out of RBCs. Therefore, we measured porphyrin levels in the blood of Lan(−) individuals. The porphyrin levels in RBCs from these individuals were slightly elevated (2.1 µmol ± 0.2 (N = 4 individuals), where the normal range is 0.1-1.9 µmol/l), but, more strikingly, the porphyrin levels in RBCs were very low and actually below the detection threshold (<5.0 nmol/l (N = 4 individuals), where the normal range is 6.5-20.0 nmol/l). Although these findings were fully consistent with the absence of porphyria symptoms 15 in Lan(−) individuals, they confirmed that ABCB6 is involved in porphyrin export from RBCs. However, the modest increase of porphyrin levels in RBCs in ABCB6 −/− individuals suggests that another porphyrin transporter of the RBC membrane, such as the breast cancer resistance protein (BCRP, also known as ABCG2; Fig. 2c, bottom) 16 , may compensate for the absence of ABCB6 at the plasma membrane of RBCs. In fact, we show in an accompanying paper 17 that ABCG2 −/− individuals have similarly impaired porphyrin levels in the blood, indicating that ABCG2 and ABCB6 have similar roles in porphyrin export from RBCs. Yet, ABCG2 does not fully replace ABCB6 when the latter is absent and vice versa; otherwise, ABCB6 −/− or ABCG2 −/− individuals would not show impaired porphyrin levels in the blood.
As the Lan antigen is carried by ABCB6 and OSK43 is suitable for flow cytometry analysis of native cells, we used OSK43 to evaluate cell surface expression of ABCB6 in different cell lines. We found the Lan antigen on HepG2 hepatocellular carcinoma (HCC) cells but not on A-498 renal cell carcinoma (RCC), A-431 squamous cell carcinoma (SCC), MOLT-4 acute lymphoblastic leukemia (ALL) or HeLa cervical cancer cells (Fig. 3a-e) . When we examined another HCC cell line, HuH-7, we also detected the Lan antigen (Fig. 3f) . Expression of ABCB6 at the plasma membrane of HepG2 and HuH-7 cells may be either related to their hepatic origin or acquired during hepatocarcinogenesis. Future studies will be necessary to dissect the role of ABCB6 at the plasma membrane of human hepatocytes in health and disease. Nevertheless, it is worth mentioning that overexpression of ABCB6 has been observed in HCC compared with surrounding non-malignant tissue and may contribute to multidrug resistance in HCC 18 .
In summary, we show in this report that ABCB6 is responsible for a new blood group system, currently defined by the Lan antigen, that is present at the plasma membrane of RBCs and of HCC cells. A Lan-specific monoclonal antibody (OSK43) has been developed and will greatly facilitate the identification of Lan(−) blood donors. In elucidating the genetic basis of the Lan(−) blood type, we have uncovered ten null mutations of ABCB6 (Fig. 2e and Table 1 ). No defective alleles of ABCB6 have previously been reported, and it was not known whether complete deficiency of this porphyrin transporter was fatal. These results indicate that not only is complete deficiency in ABCB6 viable, but it is asymptomatic. Nevertheless, it will be necessary to closely monitor Lan(−) (ABCB6 −/− ) individuals, especially those treated with drugs potentially transported by ABCB6, because this deficiency may alter the pharmacokinetics of these drugs or result in adverse effects such as hepatotoxity.
URLs. ISBT blood group terminology, http://www.isbtweb.org/ working-parties/red-cell-immunogenetics-and-terminology/.
MeTHOds
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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